hotspot -WSS

hotspot

author：leisure time 2025-10-01 21:33:34 - browse：28174

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Millions may soon lose Medicaid when they don't have to

Wikipedia

WSS

Mom launches Girl Scout troop for LGBTQ youth in Texas

Biden administration plans revamp of organ transplant system

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Eli Lilly’s Mounjaro succeeds in second weight

Intermittent fasting comes with a heart risk? Not so fast

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

focus

hotspot

focus

Psychedelics group wrestles with new pharma identity

How to fix the rural physician shortage in the U.S.

ChatGPT in medicine: STAT answers readers' burning questions

FDA approves first new drug developed for postpartum depression

Moonlake's readout produced a cash windfall. Risks remain

Colonoscopy prep: Liquid

State Dept. review finds Biden bears some blame for Afghanistan failures

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

The high cost of giving birth even with insurance

Xenotransplantation trials will require adjusting expectations, experts say

Wikipedia

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

App could help diagnose ear infections more accurately — and at home

AstraZeneca to buy developer of next

Wikipedia

Wikipedia

focus

knowledge